Sign In
Buy OCX
$3.20
+0 (+0%)
At Close: Sep 16, 2025
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
08:27am, Wednesday, 06'th Dec 2023
Significant unmet need for regulated product in $2B US testing market Opportunity for expedited pathway for kitted product in development IRVINE, CA, December 06, 2023 – Oncocyte Corporation (NASDAQ
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
08:00am, Wednesday, 06'th Dec 2023
- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte
Oncocyte Reports Third Quarter 2023 Financial Results
12:32pm, Thursday, 09'th Nov 2023
-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m.
OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript
09:36am, Thursday, 09'th Nov 2023
OncoCyte Corporation (NASDAQ:OCX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Stephanie Prince - IR, PCG Advisory Josh Riggs - President & CEO Conference Call Pa
Oncocyte to Announce Third Quarter 2023 Financial Results
08:30am, Friday, 03'rd Nov 2023
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET
OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript
12:06pm, Thursday, 10'th Aug 2023
OncoCyte Corporation (NASDAQ:OCX ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call P
Oncocyte To Announce First Quarter 2023 Financial Results
04:59pm, Thursday, 27'th Apr 2023
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results o
Broadwood Partners Now Owns 33.3% of OncoCyte
10:23pm, Monday, 10'th Apr 2023
Fintel reports that Broadwood Partners has filed a 13D/A form with the SEC disclosing ownership of 57.13MM shares of OncoCyte Corp (OCX).
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
04:01pm, Wednesday, 29'th Mar 2023
IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earning
3 Medical Services Stocks to Buy Amid Industry Challenges
12:15pm, Friday, 10'th Mar 2023
The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most.
Viatris (VTRS) Matches Q4 Earnings Estimates
12:25pm, Monday, 27'th Feb 2023 Zacks Investment Research
Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Oncocyte Completes Razor Genomics Transaction
01:00pm, Wednesday, 22'nd Feb 2023 GlobeNewswire Inc.
Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
01:00pm, Friday, 06'th Jan 2023 Benzinga
Gainers
OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products t
GlycoMimetics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
04:11pm, Wednesday, 28'th Dec 2022 Benzinga
The Dow Jones settled slightly higher on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around t
Oncocyte cuts 40% of staff
08:19am, Friday, 16'th Dec 2022
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its
